Pharmacokinetic Study of Levosulpiride
Primary Purpose
Dyspepsia
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Levosulpiride
Sponsored by
About this trial
This is an interventional basic science trial for Dyspepsia focused on measuring levosulpiride, pharmacokinetics, adverse effects, bioavailability
Eligibility Criteria
Inclusion Criteria:
- body mass index between19 and 24 kg/m2
- negative for HIV and hepatitis B
- had no clinical important findings on health tests
- thorax radiography and ECG with no abnormalities
- normal blood pressure values
- heart rate
Exclusion Criteria:
- any drug treatment within 2 weeks before starting the study
- participation in another clinical study within the previous 3 months
- alcoholism and smoking
- pregnancy
- breast-feeding
- hypocalcemia
- blood donation or participation in other clinical trials within 3 months before enrollment in the study
- sitting blood pressure <80/50 mm Hg or >140/100 mm Hg
- A ventricular rate <60 beats/min or >100 beats/min at rest
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
part 1
part 2
Arm Description
12 subjects successively received a single dose of levosulpiride tablets 25, 50, or 100 mg via oral administration and 50-mg of levosulpiride tablets 3 times a day for 7 days.
30 subjects were randomly assigned to 1 of 3 treatment groups (25, 50, or 75 mg) via i.m. administration, the 50-mg group subjects also received levosulpiride by i.v. route and repeated administration by i.m. route (twice a day for 3 days).
Outcomes
Primary Outcome Measures
Cmax
Peak concentration
Area under the curve-AUC
Area under the curve - plasma concentration
Clearance-CL
Clearance
Apparent volume of distribution-V
The apparent volume of distribution
Secondary Outcome Measures
Safety (adverse events)
adverse events
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02481583
Brief Title
Pharmacokinetic Study of Levosulpiride
Official Title
Tolerability and Pharmacokinetic Comparison of Oral, Intramuscular and Intravenous Administration of Levosulpiride After Single and Multiple Doses in Fasting Healthy Chinese Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
June 2015
Overall Recruitment Status
Completed
Study Start Date
March 2013 (undefined)
Primary Completion Date
May 2013 (Actual)
Study Completion Date
May 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Wuhan Union Hospital, China
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study was to characterise the pharmacokinetic properties and assess the safety of different formulations of levosulpiride in healthy Chinese volunteers.
Detailed Description
Levosulpiride was administered to 42 healthy male and female (1:1) subjects as tablet (orally) and injection (intramuscularly and intravenously) formulations. Blood samples were collected at regular intervals after single and multiple drug administration. The concentration of levosulpiride in plasma was determined using a validated high performance liquid chromatography-tandem mass spectrometry method. Non-compartmental analysis was performed to estimate pharmacokinetic parameters. The analysis of variance was used to test for linearity and assess the effect of gender on the pharmacokinetic properties of the study drug. Adverse effects were monitored using investigators' questionnaires and subjects' spontaneous reports, vital sign measurements, hematology, clinical chemistry, and electrocardiogram.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dyspepsia
Keywords
levosulpiride, pharmacokinetics, adverse effects, bioavailability
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
42 (Actual)
8. Arms, Groups, and Interventions
Arm Title
part 1
Arm Type
Experimental
Arm Description
12 subjects successively received a single dose of levosulpiride tablets 25, 50, or 100 mg via oral administration and 50-mg of levosulpiride tablets 3 times a day for 7 days.
Arm Title
part 2
Arm Type
Experimental
Arm Description
30 subjects were randomly assigned to 1 of 3 treatment groups (25, 50, or 75 mg) via i.m. administration, the 50-mg group subjects also received levosulpiride by i.v. route and repeated administration by i.m. route (twice a day for 3 days).
Intervention Type
Drug
Intervention Name(s)
Levosulpiride
Intervention Description
different formulations of levosulpiride
Primary Outcome Measure Information:
Title
Cmax
Description
Peak concentration
Time Frame
two days
Title
Area under the curve-AUC
Description
Area under the curve - plasma concentration
Time Frame
two days
Title
Clearance-CL
Description
Clearance
Time Frame
two days
Title
Apparent volume of distribution-V
Description
The apparent volume of distribution
Time Frame
two days
Secondary Outcome Measure Information:
Title
Safety (adverse events)
Description
adverse events
Time Frame
one month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
body mass index between19 and 24 kg/m2
negative for HIV and hepatitis B
had no clinical important findings on health tests
thorax radiography and ECG with no abnormalities
normal blood pressure values
heart rate
Exclusion Criteria:
any drug treatment within 2 weeks before starting the study
participation in another clinical study within the previous 3 months
alcoholism and smoking
pregnancy
breast-feeding
hypocalcemia
blood donation or participation in other clinical trials within 3 months before enrollment in the study
sitting blood pressure <80/50 mm Hg or >140/100 mm Hg
A ventricular rate <60 beats/min or >100 beats/min at rest
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Weiyong Li
Organizational Affiliation
HUST/Union Hospital
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
26404395
Citation
Xu M, Zhou Y, Ni Y, He X, Li H, Sattar H, Chen H, Li W. Tolerability and Pharmacokinetic Comparison of Oral, Intramuscular, and Intravenous Administration of Levosulpiride After Single and Multiple Dosing in Healthy Chinese Volunteers. Clin Ther. 2015 Nov 1;37(11):2458-67. doi: 10.1016/j.clinthera.2015.08.024. Epub 2015 Sep 26.
Results Reference
derived
Learn more about this trial
Pharmacokinetic Study of Levosulpiride
We'll reach out to this number within 24 hrs